Acknowledging World AIDS Day on December 1, President Obama announced that the National Institutes of Health (NIH) would reallocate $100 million over the next 3 years towards HIV cure research and donate up to $5 billion to the Global Fund to Fight AIDS, Tuberculosis and Malaria. In other funding news, NASTAD announced last week that there are currently no people with HIV on AIDS Drug Assistance Program (ADAP) waiting lists.
A major shift in the global anti-tuberculosis (TB) strategy was announced at the Stop TB Symposium just prior to the 44th Union World Conference on Lung Health this month in Paris. Instead of setting modest targets for incremental improvements in TB control, which has been the norm for the past few decades, the TB community -- clearly driven by TB/HIV activism -- is now calling for a global effort to eliminate the ancient disease.
The final day of AASLD Liver Meeting, recently held in Washington, DC, featured an overview of the status of new hepatitis C therapies, similarities between HCV and HIV, and a look towards the future of hepatitis C treatment. The development of next-generation HCV drugs has been remarkably rapid and experts agree that it may soon be possible to cure all patients with hepatitis C, but access is likely to be a challenge.
HIVandHepatitis.com coverage of the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013) in Boston, November 1-5, 2013.
Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, HIV/HBV and HIV/HCV coinfection, and prevention and treatment of hepatocellular carcioma.